Fmr LLC Trims Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

FMR LLC reduced its stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 10.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,749,156 shares of the company's stock after selling 873,312 shares during the period. FMR LLC owned 4.84% of Neumora Therapeutics worth $102,366,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its holdings in Neumora Therapeutics by 139.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company's stock valued at $9,224,000 after buying an additional 406,891 shares in the last quarter. Callan Capital LLC increased its position in Neumora Therapeutics by 222.6% during the second quarter. Callan Capital LLC now owns 661,194 shares of the company's stock worth $6,500,000 after purchasing an additional 456,207 shares during the last quarter. Auour Investments LLC acquired a new stake in Neumora Therapeutics during the third quarter worth about $3,302,000. Cerity Partners LLC purchased a new position in Neumora Therapeutics during the third quarter worth about $3,209,000. Finally, Bank of New York Mellon Corp grew its position in Neumora Therapeutics by 474.1% in the second quarter. Bank of New York Mellon Corp now owns 235,593 shares of the company's stock worth $2,316,000 after acquiring an additional 194,559 shares during the period. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

Neumora Therapeutics Stock Performance

Shares of NASDAQ:NMRA traded down $0.11 during trading on Thursday, hitting $9.66. The company's stock had a trading volume of 1,452,529 shares, compared to its average volume of 740,281. Neumora Therapeutics, Inc. has a fifty-two week low of $8.33 and a fifty-two week high of $21.00. The business has a 50 day moving average price of $12.42 and a two-hundred day moving average price of $11.45. The company has a market capitalization of $1.56 billion, a PE ratio of -5.17 and a beta of 3.34.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same period in the prior year, the firm posted ($1.14) earnings per share. As a group, equities analysts expect that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on NMRA shares. Needham & Company LLC reiterated a "buy" rating and set a $23.00 price target on shares of Neumora Therapeutics in a report on Wednesday, November 13th. HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Neumora Therapeutics in a research report on Wednesday, November 13th. JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an "overweight" rating to a "neutral" rating and lowered their price objective for the stock from $18.00 to $15.00 in a research report on Tuesday, November 5th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $29.00 target price on shares of Neumora Therapeutics in a report on Friday, November 22nd. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $21.67.

Insider Activity at Neumora Therapeutics

In related news, Director Matthew K. Fust sold 14,049 shares of the company's stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $17.03, for a total value of $239,254.47. Following the completion of the transaction, the director now directly owns 20,100 shares of the company's stock, valued at $342,303. This represents a 41.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Robert A. Lenz sold 30,788 shares of the firm's stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total transaction of $363,606.28. Following the sale, the insider now directly owns 339,205 shares in the company, valued at approximately $4,006,011.05. The trade was a 8.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,400 shares of company stock valued at $686,361 over the last 90 days. 26.40% of the stock is owned by corporate insiders.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.